Michael Flamm - Academia.edu (original) (raw)

Papers by Michael Flamm

Blood, 1982

The membrane lipid fluidity of normal human erythrocytes was modified by enrichment and depletion... more The membrane lipid fluidity of normal human erythrocytes was modified by enrichment and depletion in cholesterol, and the expression of I and SP1 antigens was assayed by quantitative hemagglutination from 4 degrees to 24 degrees C by use of a continuous flow system. Below 16 degrees--18 degrees C, cholesterol enrichment increased and cholesterol depletion decreased percent agglutination. As temperatures approached approximately 18 degrees--20 degrees C, differences in agglutination between modified and unmodified erythrocytes became insignificant despite marked differences in lipid fluidity at that temperature. Thus, fluidity changes alone cannot be responsible for the effect of membrane cholesterol on cold agglutination. In an additional study, the temperature dependence of a relative equilibrium association constant, estimated by probit analysis of percent agglutination at various antisera concentrations, was biphasic with a sharp break at 16 degrees C. Our studies are consistent ...

Leukemia & Lymphoma, 2008

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf ... more Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf This article maybe used for research, teaching and private study purposes. Any substantial or systematic reproduction, redistribution , reselling , loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden. The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

American Journal of Hematology, 1996

A novel method involving the packaging of phage particles was used to introduce cosmids containin... more A novel method involving the packaging of phage particles was used to introduce cosmids containing components of the human beta-globin locus control region (LCR) and the human (A)gamma, delta, and beta globin genes into mouse erythroleukemia (MEL) cells. After stable transfection, MEL clones were selected and analyzed for expression of human genes. Both (A)gamma and beta globin mRNA were expressed in these clones, indicating that MEL cells do not suppress transcription of the human gamma globin gene. The variability of human (A)gamma vs. beta globin expression from clone to clone prevents a clear delineation of differences in the expression of these two genes with a cosmid in which a region potentially involved in gamma-to-beta switching has been deleted. The results suggest that MEL cells are capable of supporting human gamma expression, despite their predominantly adult phenotype.

Blood

4479 Background: With the introduction of tyrosine kinase inhibitors (TKIs), CML treatment and mo... more 4479 Background: With the introduction of tyrosine kinase inhibitors (TKIs), CML treatment and monitoring have undergone significant advances over the last decade. With prolonged survival, it is important to better understand factors that impact therapeutic decisions, particularly when a change in treatment is warranted, and to better understand healthcare resource utilization. Methods: A modified Delphi panel study was conducted, utilizing initial in-depth interviews with 16 CML treating physicians to develop key themes and questions for testing, followed by an on-line survey to capture initial estimates regarding treatment patterns, monitoring and healthcare use. The results were presented and discussed at a live meeting to develop consensus on the estimates provided and complete a second round of surveying. A panel of 7 CML treating physicians, based on their CML treatment experience and pre-established Delphi panel guidelines, from across U.S. was convened. The range and certain...

Leukemia Research, 2002

We report a patient with Philadelphia chromosome positive (Ph +ve) chronic myelogenous leukemia (... more We report a patient with Philadelphia chromosome positive (Ph +ve) chronic myelogenous leukemia (CML), treated with hydroxyurea alone, who upon disease progression developed an additional Ph - ve clone containing chromosomal abnormalities typical of myelodysplastic syndrome (MDS). Retrospective analysis of a cryopreserved stem cell specimen from diagnosis confirmed that this second clone developed during the course of treatment. The development of a clone with additional cytogenetic abnormalities in CML has only been reported after leukemogenic treatment, stem cell transplantation or interferon. We report a case of secondary Ph - ve MDS/AML during blast crisis in a patient treated with hydroxyurea for CML.

Leukemia & Lymphoma, 2003

As both fludarabine and rituximab are active against indolent lymphoproliferative disorders, we h... more As both fludarabine and rituximab are active against indolent lymphoproliferative disorders, we have studied the combination of fludarabine and rituximab in patients with low-grade lymphoma and chronic lymphocytic leukemia (CLL) in phase I/II fashion. Of 33 patients enrolled, 21(63.6%) had low-grade lymphoma and 12 (36.4%) had CLL. They received fludarabine 30 mg/m2 on days 1-4 and rituximab 125, 250 or 375 mg/m2 on day 5 at intervals of 28 days to a maximum of 8 cycles. Three patients were removed from the study because of rituximab-associated anaphylaxis and four because of prolonged hematopoietic toxicity. Toxicity and responsiveness did not differ at the different dose levels of rituximab. For 29 evaluable patients, responses were seen in 82.8% and complete responses in 34.5%. Of 7 responding patients not referred for stem cell transplantation, 6 remain in complete remission at a median follow-up of 16 months (range 4-30 months). Of 13 previously untreated patients, all responded and 46.2% had a complete response. Of 16 previously treated patients, 68.5% responded and 25% had a complete response. The combination of fludarabine and rituximab has major activity and acceptable toxicity in patients with low-grade lymphoma and CLL.

Journal of Theoretical Biology, 1977

Abstract The regulatory effect of hormones on a steady-state process that consists of the mediate... more Abstract The regulatory effect of hormones on a steady-state process that consists of the mediated transport of a substrate across a membrane and a consecutive enzymic reaction is examined theoretically. The regulation of such a process depends not only on the effect of ...

Journal of theoretical biology, 1977

The regulatory effect of hormones on a steady-state process that consists of the mediated transpo... more The regulatory effect of hormones on a steady-state process that consists of the mediated transport of a substrate across a membrane and a consecutive enzymic reaction is examined theoretically. The regulation of such a process depends not only on the effect of ...

Leukemia research, 2002

The structure 1??? 3 and functions 4??? 10 of the human erythrocyte are influenced by the composi... more The structure 1??? 3 and functions 4??? 10 of the human erythrocyte are influenced by the composition and organization of the membrane lipids. The outer (exofacial) and inner (endofacial) leaflets of the erythrocyte membrane differ in lipid composition 11, 12, and ...

Biochemical and Biophysical Research Communications, 1980

Biochemical and Biophysical Research Communications, 1979

Abstract The probe, 1, 6-diphenyl-1, 3, 5-hexatriene (DPH) was used to determine if tumor promoti... more Abstract The probe, 1, 6-diphenyl-1, 3, 5-hexatriene (DPH) was used to determine if tumor promoting agents alter cell membranes. The active tumor promoters TPA (12-0-tetra-decanoyl-phorbol-13-acetate), PDD (phorbol-12, 13-didecanoate) and PDB (phorbol-12, ...

Biochimica et Biophysica Acta (BBA) - Biomembranes, 1982

** The term 'transmon temperature' as used m t~s report to denote the break point temperature obs... more ** The term 'transmon temperature' as used m t~s report to denote the break point temperature observed in an Arrhemus plot Gaven the complexaty of the erythrocyte membrane

Annals of the New York Academy of Sciences, 1983

Leukemia & …, 2003

Proceedings of the …, 1991

Proc. Natl. Acad. Sci. USA Vol. 88, pp. 8953-8957, October 1991 Biochemistry ... A DNA-binding fa... more Proc. Natl. Acad. Sci. USA Vol. 88, pp. 8953-8957, October 1991 Biochemistry ... A DNA-binding factor in adult hematopoietic cells interacts with a pyrimidine-rich domain upstream from the human 6globin gene ... (hemoglobin switching/Sl nuclease-sensitive sites/H-DNA)